Lapatinib (Lap) is an inhibitor that can target the tyrosine kinase domains of HER2 and suppress the phosphorylation and signaling of MAPK and Akt/mTOR oncogenic pathways, inhibiting cancer proliferation and leading to apoptosis. This evidence concerns the gene AKT1 and cancer.